{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:22:45Z","timestamp":1790241765465,"version":"4.1.0"},"reference-count":111,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL114910"],"award-info":[{"award-number":["HL114910"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a catastrophic complication of one of the most common and devastating autoimmune diseases. Once diagnosed, it becomes the leading cause of mortality among this patient population. Screening modalities and risk assessments have been designed and validated by various organizations and societies in order to identify patients early in their disease course and promptly refer them to expert centers for a hemodynamic assessment and formal diagnosis. Moreover, several large multicenter clinical trials have now included patients with SSc-PAH to assess their response to therapy. Despite an improved understanding of the condition and significant advances in supportive and targeted therapy, outcomes have remained far from optimal. Therefore, rigorous phenotyping and search for novel therapies are desperately needed for this devastating condition.<\/jats:p>","DOI":"10.3390\/diagnostics11050911","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T06:13:45Z","timestamp":1621491225000},"page":"911","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7584-2489","authenticated-orcid":false,"given":"Mario","family":"Naranjo","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-4975","authenticated-orcid":false,"given":"Paul M.","family":"Hassoun","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-140-1-200401060-00010","article-title":"Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis","volume":"140","author":"Jimenez","year":"2004","journal-title":"Ann. Intern Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/annrheumdis-2011-200265","article-title":"Pulmonary Arterial Hyper-tension Quality Enhancement Research Initiative, I. The pulmonary arterial hypertension quality enhancement research ini-tiative: Comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH","volume":"71","author":"Clements","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.22069","article-title":"Clinical differences between idiopathic and scleroderma-related pulmonary hypertension","volume":"54","author":"Fisher","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.100245","article-title":"Prevalence of pul-monary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies","volume":"37","author":"Avouac","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: Results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.semarthrit.2014.03.002","article-title":"Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study","volume":"44","author":"Hsu","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pul-monary arterial hypertension: Baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/art.38172","article-title":"Recommendations for Screening and Detection of Connective Tissue Disease\u2013Associated Pulmonary Arterial Hypertension","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13075-016-0933-1","article-title":"Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: A cohort study","volume":"18","author":"Pasarikovski","year":"2016","journal-title":"Arthritis Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.healun.2004.12.113","article-title":"Long-term outcome of bosentan treatment in idiopathic pul-monary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases","volume":"24","author":"Girgis","year":"2005","journal-title":"J. Heart Lung Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","article-title":"Diagnosis and Assessment of Pulmonary Arterial Hypertension","volume":"54","author":"Badesch","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1378\/chest.12-2396","article-title":"Systemic Sclerosis-Associated Pulmonary Arterial Hypertension","volume":"144","author":"Chaisson","year":"2013","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1183\/09059180.00003811","article-title":"Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus","volume":"20","author":"Johnson","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12016-011-8265-z","article-title":"The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension","volume":"44","author":"Kherbeck","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MCP.0000000000000192","article-title":"Right ventricle dysfunction in pulmonary hypertension: Mechanisms and modes of detection","volume":"21","author":"Bourji","year":"2015","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.200912-1820OC","article-title":"Hemodynamic Predictors of Survival in Scleroderma-related Pulmonary Arterial Hypertension","volume":"182","author":"Campo","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccl.2020.01.001","article-title":"Right Heart Failure: A Hemodynamic Review","volume":"38","author":"Viray","year":"2020","journal-title":"Cardiol. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1086\/679607","article-title":"The right ventricle in scleroderma (2013 Grover Conference Series)","volume":"5","author":"Hassoun","year":"2015","journal-title":"Pulm. Circ."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1161\/CIRCULATIONAHA.116.022082","article-title":"Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension","volume":"133","author":"Hsu","year":"2016","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Morrisroe, K., The Australian Scleroderma Interest Group (ASIG), Huq, M., Stevens, W., Rabusa, C., Proudman, S.M., and Nikpour, M. (2016). Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: Results from a large multicenter cohort study. Bmc Pulm. Med., 16.","DOI":"10.1186\/s12890-016-0296-z"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cu-taneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in Systemic Sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2147\/BTT.S3188","article-title":"IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts","volume":"2","author":"Mouthon","year":"2008","journal-title":"Biol. Targets Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3899\/jrheum.101243","article-title":"Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population","volume":"38","author":"Hinchcliff","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0025-6196(11)61030-6","article-title":"Pulmonary hypertension in patients with interstitial lung diseases","volume":"82","author":"Ryu","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1183\/09031936.00078411","article-title":"ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre","volume":"39","author":"Hurdman","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/rheumatology\/40.4.453","article-title":"Pulmonary hypertension in systemic sclerosis: Risk factors for progression and consequences for survival","volume":"40","author":"MacGregor","year":"2001","journal-title":"Rheumatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/art.30423","article-title":"Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies","volume":"63","author":"Girgis","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.24267","article-title":"Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease","volume":"60","author":"Mathai","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/BOR.0b013e32833dfbd8","article-title":"Cardiac complications of systemic sclerosis: Recent progress in diagnosis","volume":"22","author":"Boueiz","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00296-015-3382-2","article-title":"Cardiac involvement in systemic sclerosis: Dif-ferences between clinical subsets and influence on survival","volume":"37","author":"Pizzi","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"993","DOI":"10.4330\/wjc.v6.i9.993","article-title":"Cardiac manifestations in systemic sclerosis","volume":"6","author":"Lambova","year":"2014","journal-title":"World J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/ard.2006.057760","article-title":"Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis","volume":"67","author":"Gressin","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00109-013-1059-4","article-title":"A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension","volume":"91","author":"Sutendra","year":"2013","journal-title":"J. Mol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Natarajan, R., Drake, J.I., Bogaard, H.J., Fawcett, P.M., Clifton, B., Gao, Y., and Voelkel, N.F. (2010, January 14\u201319). The Molecular Signature Of The Right Heart Failure Program In Chronic Severe Pulmonary Hypertension. Proceedings of the American Thoracic Society 2010 International Conference, New Orleans, LA, USA.","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A6586"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1148\/radiol.10100725","article-title":"Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemody-namics in patients with pulmonary arterial hypertension","volume":"258","author":"Skrok","year":"2011","journal-title":"Radiology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/j.lpm.2014.06.007","article-title":"Update in systemic sclerosis-associated pulmonary arterial hypertension","volume":"43","author":"Gashouta","year":"2014","journal-title":"La Presse M\u00e9dicale"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1183\/09031936.00074309","article-title":"Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension","volume":"35","author":"Mathai","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1164\/rccm.200712-1876OC","article-title":"Hyponatremia Predicts Right Heart Failure and Poor Survival in Pulmonary Arterial Hypertension","volume":"177","author":"Forfia","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1183\/09059180.00005112","article-title":"Early detection and management of pulmonary arterial hypertension","volume":"21","author":"Humbert","year":"2012","journal-title":"Eur. Respir. Rev."},{"key":"ref_48","first-page":"1","article-title":"Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension","volume":"19","author":"Morrisroe","year":"2017","journal-title":"Arthritis Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/IBPC.S232038","article-title":"Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis","volume":"13","author":"Almaaitah","year":"2020","journal-title":"Integr. Blood Press. Control"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT study","volume":"73","author":"Coghlan","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respir-atory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"46","author":"Galie","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Fransen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/rheumatology\/ken488","article-title":"Risk factors for death and the 3-year survival of patients with systemic sclerosis: The French ItinerAIR-Sclerodermie study","volume":"48","author":"Hachulla","year":"2009","journal-title":"Rheumatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/art.24525","article-title":"The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France","volume":"60","author":"Hachulla","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ajh.2010.188","article-title":"Diagnostic value of transthoracic Doppler echocardiography in pul-monary hypertension: A meta-analysis","volume":"23","author":"Zhang","year":"2010","journal-title":"Am. J. Hypertens."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/hrt.2010.212084","article-title":"Diagnostic accuracy of echocardiography for pulmonary hypertension: A systematic review and meta-analysis","volume":"97","author":"Janda","year":"2011","journal-title":"Heart"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ni, J.R., Yan, P.J., Liu, S.D., Hu, Y., Yang, K.H., Song, B., and Lei, J.Q. (2019). Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension: A systematic review and meta-analysis. BMJ Open, 9.","DOI":"10.1136\/bmjopen-2019-033084"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1164\/rccm.200604-547OC","article-title":"Tricuspid Annular Displacement Predicts Survival in Pulmonary Hypertension","volume":"174","author":"Forfia","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3899\/jrheum.110512","article-title":"Tri-cuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension","volume":"38","author":"Mathai","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3899\/jrheum.090997","article-title":"Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic scle-rosis","volume":"37","author":"Cavagna","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/art.23187","article-title":"High N-terminal pro\u2013brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis","volume":"58","author":"Allanore","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/rheumatology\/keh067","article-title":"Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis","volume":"43","author":"Mukerjee","year":"2004","journal-title":"Rheumatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/BOR.0b013e32834ba6a7","article-title":"Pulmonary hypertension: Screening and evaluation in scleroderma","volume":"23","author":"York","year":"2011","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_64","first-page":"2431","article-title":"Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis","volume":"34","author":"Bezante","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1136\/ard.2008.095836","article-title":"Cardiac magnetic resonance imaging in systemic sclerosis: A cross-sectional observational study of 52 patients","volume":"68","author":"Hachulla","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/rheumatology\/kep187","article-title":"Ventricular mass index correlates with pulmonary artery pressure and predicts survival in suspected systemic sclerosis-associated pulmonary arterial hypertension","volume":"48","author":"Hagger","year":"2009","journal-title":"Rheumatology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-018-0709-5","article-title":"An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Review of the Current Literature","volume":"20","author":"Sundaram","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","article-title":"Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension","volume":"192","author":"Hassoun","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1183\/13993003.00678-2018","article-title":"Haemody-namics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension","volume":"52","author":"Weatherald","year":"2018","journal-title":"Eur. Respir. J"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2010.08.004","article-title":"Pulmonary Hypertension in Systemic Sclerosis","volume":"41","author":"Chatterjee","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/eurheartj\/ehq170","article-title":"Long-term response to cal-cium-channel blockers in non-idiopathic pulmonary arterial hypertension","volume":"31","author":"Montani","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1602275","DOI":"10.1183\/13993003.02275-2016","article-title":"Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort","volume":"49","author":"Vandecasteele","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1802148","DOI":"10.1183\/13993003.02148-2018","article-title":"An overview of the 6th World Symposium on Pulmonary Hypertension","volume":"53","author":"Galie","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1801889","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk strat-ification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Galie","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1700889","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC\/ERS-Based Risk Assessment Strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Con-tinuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.126.2.420","article-title":"Treprostinil, a prostacyclin ana-logue, in pulmonary arterial hypertension associated with connective tissue disease","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A dou-ble-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am. J. Respir Crit Care Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ejim.2011.02.005","article-title":"Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease","volume":"22","author":"Caravita","year":"2011","journal-title":"Eur. J. Intern. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the Treatment of Pulmonary Arterial Hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_84","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hy-pertension associated with connective tissue disease","volume":"34","author":"Badesch","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMc051946","article-title":"Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil Therapy for Pulmonary Arterial Hypertension","volume":"119","author":"Brundage","year":"2009","journal-title":"Circulation"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijcard.2017.02.094","article-title":"Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease","volume":"235","author":"Denton","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan Therapy for Pulmonary Arterial Hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/ard.2007.079921","article-title":"Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases","volume":"67","author":"Denton","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.rmed.2016.06.018","article-title":"Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)\u2014A subgroup analysis of the ARIES-E clinical trial","volume":"117","author":"Fischer","year":"2016","journal-title":"Respir. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hy-pertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1164\/rccm.201507-1456OC","article-title":"Comparison of Treatment Response in Idiopathic and Connective Tissue Disease\u2013associated Pulmonary Arterial Hypertension","volume":"192","author":"Rhee","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the Treatment of Pulmonary Arterial Hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: Results from PATENT-1 and PATENT-2","volume":"76","author":"Humbert","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12931-018-0957-y","article-title":"Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pul-monary hypertension (the RIVER study)","volume":"19","author":"Marra","year":"2018","journal-title":"Respir. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Sato, T., Ambale-Venkatesh, B., Lima, J.A., Zimmerman, S.L., Tedford, R.J., Fujii, T., Hulme, O.L., Pullins, E.H., Corona-Villalobos, C.P., and Zamanian, R.T. (2018). The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: Cardiac magnetic resonance feature tracking study. Pulm. Circ., 8.","DOI":"10.1177\/2045893217748307"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-017-0262-z","article-title":"Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study","volume":"18","author":"Coghlan","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40256-017-0260-1","article-title":"Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial","volume":"18","author":"Jansa","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1183\/09031936.00039212","article-title":"Major bleeding with vitamin K antagonist anti-coagulants in pulmonary hypertension","volume":"41","author":"Henkens","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1161\/CIRCULATIONAHA.114.010921","article-title":"Response to Letters Regarding Article, \u201cAnticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)\u201d","volume":"130","author":"Olsson","year":"2014","journal-title":"Circulation"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.115.018435","article-title":"Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)","volume":"132","author":"Preston","year":"2015","journal-title":"Circulation"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Calderone, A., Stevens, W., Prior, D., Nandurkar, H., Gabbay, E., Proudman, S.M., Williams, T., Celermajer, D., Sahhar, J., and Wong, P.K. (2016). Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pul-monary arterial hypertension: The SPHInX study protocol. BMJ Open, 6.","DOI":"10.1136\/bmjopen-2016-011028"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.130.1.182","article-title":"Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension","volume":"130","author":"Sanchez","year":"2006","journal-title":"Chest"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Zamanian, R.T., Badesch, D., Chung, L., Domsic, R.T., Medsger, T., Pinckney, A., Keyes-Elstein, L., D\u2019Aveta, C., Spychala, M., and White, R.J. (2021). Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Randomized, Placebo-controlled Trial. Am. J. Respir. Crit. Care Med.","DOI":"10.1164\/rccm.202009-3481OC"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s11926-017-0650-z","article-title":"Lung Transplantation in Patients With Systemic Sclerosis","volume":"19","author":"Shah","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.39021","article-title":"Survival of Adults With Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study","volume":"67","author":"Bernstein","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1002\/art.22264","article-title":"Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hy-pertension","volume":"54","author":"Schachna","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1378\/chest.13-3014","article-title":"Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry","volume":"146","author":"Chung","year":"2014","journal-title":"Chest"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/art.38029","article-title":"Survival and Prognostic Factors in Systemic Sclerosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis","volume":"65","author":"Dauchet","year":"2013","journal-title":"Arthritis Rheum."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/5\/911\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:04:27Z","timestamp":1760162667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/5\/911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":111,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["diagnostics11050911"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics11050911","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]}}}